"Six injections in 30 minutes"... The story of a man in his 60s receiving the second dose of 'this vaccine' in the world?

I have never heard of the development of a lung cancer vaccine before.

It seems like the research is still ongoing~

I hope that the lung cancer vaccine becomes the global standard treatment and that lung cancer is finally conquered.

I hope cancer treatment development succeeds.

Janusz Ratz, a 67-year-old born in Poland who was diagnosed with lung cancer last May, has become the first in the UK to participate in a clinical trial for a lung cancer vaccine. [Photo = Screenshot from The Sun, a UK daily newspaper]

 

Until now, the only cancer preventable by vaccination was cervical cancer, but we are approaching an era where other cancers can also be prevented with vaccines. At the end of July, the world's first clinical trial for a lung cancer vaccine was launched. Following a German woman who became the first recipient of the lung cancer vaccine, a man with lung cancer in the UK received the vaccine a few days ago. He became the second person in the world to receive the first developed lung cancer vaccine.

According to foreign media such as the UK daily The Sun, 67-year-old Janusz Ratz (born in Poland), who was diagnosed with lung cancer last May, became the first in the UK to participate in a lung cancer vaccine clinical trial and receive the vaccination. On August 20th local time, at University Hospital London, Janusz received six injections at five-minute intervals over 30 minutes. He will receive the vaccine weekly for six weeks, followed by every three weeks for 54 weeks. The vaccine is BNT116, which is called a 'game changer' for the prevention and treatment of lung cancer.

BioNTech's BNT116, developed in Germany, is based on the same mRNA technology used in Covid-19 vaccines. It introduces tumor markers of non-small cell lung cancer (NSCLC) into the immune system to induce the attack on cancer cells. The vaccine targets only cancer cells in a targeted manner without damaging healthy cells. BioNTech is a biotechnology company that develops vaccines for various diseases based on mRNA technology and is especially well known for its Covid-19 vaccine development.

A man who was accidentally diagnosed with lung cancer during a colonoscopy last May accepted a proposal to participate in a vaccine clinical trial

Yanuz, the second in the world and the first in the UK to conduct a clinical trial for a lung cancer vaccine, is a scientist and father of three children who was accidentally diagnosed with lung cancer on May 1st. Last year, he was prescribed an inhaler due to shortness of breath. In mid-February, he scheduled a colonoscopy, but his blood pressure was too high, and while preparing for a CT colonoscopy, something was discovered in his right lung.

As a result of an emergency examination, Janus was diagnosed with lung cancer. It was said that without chemotherapy, he would only live 4 to 5 months, and with chemotherapy and radiation therapy, he had a 35% chance of survival for five years. The difficult chemotherapy began, and the tumor gradually shrank. After chemotherapy, Janus was offered by Dr. Benaphip at University College London Hospital to participate in a vaccine clinical trial. After thoroughly discussing the pros and cons with his family and close acquaintances, he decided to participate in the clinical trial.

Dr. Sarah Benafif, head of the clinical research on lung cancer vaccines at University College London Hospital in the UK, said, "The strength of the clinical trial approach for lung cancer vaccines is that vaccine treatment is highly targeted at cancer cells," and "We expect a mitigating effect on lung cancer without affecting other tissues over time."

Janusz said, "I participated in this study because I hoped it would provide protection against cancer cells, but I also want it to help others and for this treatment to be more widely used."

Professor Siu Ming Lee, an advisory oncologist at University College London Hospital NHS Foundation Trust (UCLH), who is leading clinical trials in the UK, said he hopes the vaccine will prevent the recurrence of lung cancer. According to the professor, immunotherapy has made significant progress, but it still cannot successfully treat all lung cancer patients. It is expected that this vaccine could improve the survival rate of lung cancer patients.

Phase 1 clinical trial of lung cancer vaccine conducted at 34 hospitals across 7 countries worldwide

This Phase 1 clinical trial of the lung cancer vaccine is being conducted at 34 hospitals across seven countries, including the UK and Wales, with plans to recruit 130 patients. In the Phase 1 study, the safety of the BNT116 vaccine will be determined, and if successful, a Phase 2 trial will be conducted with an expanded patient sample to study the general efficacy. The larger-scale Phase 3 trial will typically compare the new treatment with standard therapy. Researchers hope that if all trials succeed, the BNT116 lung cancer vaccine will become the global standard treatment and help overcome lung cancer.

Cancer vaccines are a new frontier in cancer treatment, with immunotherapy making significant advances. Clinical trials are underway for mRNA vaccine development targeting cancers such as cancer and colon cancer, and some of the developed cancer vaccines currently work by enhancing the immune system to attack specific types of cancer cells. In April, a final Phase 3 trial related to personalized mRNA shots for melanoma also began at UCLH.

Kelley Palmer, head of cancer at the UK National Health Service, expressed optimism that this lung cancer vaccine, along with other cancer vaccines in clinical trials, could make significant progress in cancer treatment. Palmer stated, "If we succeed, this vaccine could play an innovative role in preventing cancer recurrence after initial treatment," and added, "Hospitals are collaborating with universities and industry partners to research ways to utilize the body's immune system to treat various cancers, and it is expected that more patients will participate in clinical trials in the coming years."

<Source: Comedy.com>